SkinSpirit and Allergan Aesthetics Team Up to Empower Girls Inc. and Women in STEM
In its sixth year of collaboration with Girls Inc., Allergan Aesthetics, a subsidiary of AbbVie, is pleased to welcome SkinSpirit, a leading provider of medical aesthetics and skincare, to its…
ScaleReady Awards G-Rex® Grant to Luminary Therapeutics
ScaleReady, in partnership with Wilson Wolf Manufacturing and Bio-Techne Corporation (NASDAQ: TECH), has announced that Luminary Therapeutics has been awarded a $300,000 G-Rex® Grant. This funding will facilitate rapid process…
Viatris Recognized on Forbes’ 2024 List of World’s Top Companies for Women
Global healthcare company Viatris has been named to Forbes’ World’s Top Companies for Women 2024 list, an honor awarded in collaboration with Statista, a leading statistics and industry ranking provider.…
Exelixis Reports Q3 2024 Financial Results and Corporate Update
Exelixis, Inc. (Nasdaq: EXEL) released its third-quarter financial results for 2024 and highlighted recent progress across key commercial, clinical, and pipeline milestones. Key Developments and Corporate Updates Pipeline and Clinical…
WHO Activates Global Health Emergency Corps for First Time in Response to Mpox Outbreak
In October 2024, the World Health Organization (WHO), alongside its partners and Member States, activated the Global Health Emergency Corps (GHEC) for the first time to support countries grappling with…
Tuberculosis Returns as Leading Infectious Disease Killer
The World Health Organization (WHO) has released its latest report on tuberculosis (TB), revealing that 8.2 million people were newly diagnosed in 2023—the highest number since WHO began tracking TB…
Alliance for Transformative Action on Climate and Health Restructured at General Meeting
The Alliance for Transformative Action on Climate and Health (ATACH) recently held a virtual general meeting to announce a comprehensive restructuring aimed at enhancing its responsiveness to the climate crisis…
INTerpath-009 Trial Expands V940 Clinical Program, Targeting Earlier Cancer Stages
Merck (NYSE: MRK), known as MSD in markets outside the United States and Canada, and Moderna, Inc. (Nasdaq: MRNA), have announced the launch of INTerpath-009, a pivotal Phase 3 randomized…
AbbVie Acquires Aliada Therapeutics to Strengthen Alzheimer’s and Neuroscience Commitment
AbbVie (NYSE: ABBV) has announced a definitive agreement to acquire Aliada Therapeutics, a biotechnology firm focused on developing therapies using innovative blood-brain barrier (BBB)-crossing technology aimed at treating complex central…
Astellas Updates on Marketing Authorization Application for Avacincaptad Pegol (ACP) in the EU
Astellas Pharma Inc. (TSE: 4503; President and CEO: Naoki Okamura) announced today its decision to withdraw the marketing authorization application for avacincaptad pegol intravitreal solution (ACP) from the European Medicines…
Walgreens Expands Virtual Healthcare to 30 States, Adds Lab Tests and STD Treatments
Walgreens is expanding its virtual healthcare service to enhance access for patients nationwide. As of October 1, Walgreens Virtual Healthcare is now available in 30 states, a significant increase from…
Merck and Moderna Launch Phase 3 Trial of V940 and KEYTRUDA® Combo in Non-Small Cell Lung Cancer
Merck (NYSE: MRK), also known as MSD outside the U.S. and Canada, and Moderna, Inc. (Nasdaq: MRNA), announced the launch of INTerpath-009, a Phase 3 randomized clinical trial investigating V940…